A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma
Purpose
The purpose of this study is to test the effectiveness and safety of various nivolumab combinations compared to nivolumab and ipilimumab in participants with advanced kidney cancer
Condition
- Advanced Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Advanced Renal Cell Carcinoma - Must have at least 1 lesion with measurable disease - Life expectancy of at least 3 months - Karnofsky Performance Status (KPS) must be =>70%
Exclusion Criteria
- Patients/subjects with suspected or known central nervous system metastases unless adequately treated - Patients/subjects with autoimmune disease - Patients/subjects who need daily oxygen therapy Other protocol defined inclusion/exclusion criteria apply
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Active Comparator Nivolumab + Ipilimumab |
Nivolumab + Ipilimumab |
|
Experimental Nivolumab + Relatlimab |
Nivolumab + Relatlimab |
|
Experimental Nivolumab + BMS-986205 |
Nivolumab + BMS-986205 |
|
Experimental Nivolumab + BMS-813160 |
Nivolumab + BMS-813160 (CCR2/5 dual antagonist) |
|
More Details
- Status
- Completed
- Sponsor
- Bristol-Myers Squibb